Core Insights - Alpha Cognition Inc. (NASDAQ: ACOG) has successfully advanced its first full quarter of ZUNVEYL® commercialization in Q2 2025, achieving significant early adoption in the U.S. long-term care market and a key regulatory milestone in China [1][7] Group 1: Commercial Performance - ZUNVEYL® generated approximately $2 million year-to-date net product revenue, with orders placed in over 300 nursing homes and a 65% rate of repeat ordering, indicating strong clinical confidence and operational fit [7] - The sales team engaged with more than 3,700 healthcare professionals, resulting in both new and repeat prescriptions [1][7] Group 2: Regulatory Developments - The China Medical System's New Drug Application (NDA) for ZUNVEYL has been accepted by the National Medical Products Administration (NMPA), paving the way for potential approval in China and additional filings in four other countries by year-end [7] Group 3: Clinical Research - A completed Department of Defense-funded Bomb Blast study demonstrated that ALPHA-1062 reduced neuroinflammation and toxic Tau proteins in mild traumatic brain injury (mTBI), supporting further development of the product [7]

Group 1 - Alpha Cognition Inc. reported a quarterly loss of $0.65 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.46, and compared to a loss of $0.25 per share a year ago, indicating an earnings surprise of -41.30% [1] - The company posted revenues of $1.66 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.18%, compared to zero revenues a year ago [2] - Alpha Cognition Inc. shares have increased approximately 69.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 10% [3] Group 2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for Alpha Cognition Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.48 on revenues of $3.02 million, and for the current fiscal year, it is -$1.42 on revenues of $13.81 million [7] Group 3 - The outlook for the Medical - Biomedical and Genetics industry, to which Alpha Cognition Inc. belongs, is currently in the bottom 41% of over 250 Zacks industries, which may impact the stock's performance [8]

Alpha Cognition (ACOG) Q2 2025 Earnings Call August 14, 2025 04:30 PM ET Speaker0Greetings and welcome to the AlphaCognition Earnings Call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Henry Du, Interim Chief Financial Officer, Vice President of Accounting and Finance.Thank you. You may begin.Speaker1Thank you, Sachi. Good after ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (858) 344-4375 (Registrant's Telephone Number, including Area Code) Commission file number: 001-42403 | British Columbia | N/A | | --- | --- | | (State or o ...

Core Viewpoint - Alpha Cognition Inc. (ACOG) has received a Zacks Rank 1 (Strong Buy) upgrade, indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in stock price movements [4]. Recent Performance and Future Outlook - Alpha Cognition Inc. is expected to earn -$1.42 per share for the fiscal year ending December 2025, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for Alpha Cognition Inc. has increased by 49.3%, reflecting a positive trend in earnings estimates [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Alpha Cognition Inc. to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating strong potential for near-term price appreciation [10].

Group 1 - Alpha Cognition Inc. (ACOG) is currently ranked 7 in the Zacks Sector Rank among 989 companies in the Medical group, indicating strong performance relative to peers [2] - ACOG has a Zacks Rank of 1 (Strong Buy), suggesting it is poised to outperform the broader market in the next one to three months [3] - Over the past three months, the Zacks Consensus Estimate for ACOG's full-year earnings has increased by 49.3%, reflecting improved analyst sentiment and a positive earnings outlook [4] Group 2 - Year-to-date, ACOG has gained approximately 58.4%, while the average performance of Medical group stocks has declined by about 3.7%, demonstrating ACOG's strong outperformance [4] - ACOG belongs to the Medical - Biomedical and Genetics industry, which includes 497 companies and is currently ranked 85 in the Zacks Industry Rank; this industry has seen an average loss of 3.4% this year, further highlighting ACOG's superior performance [6] - Astellas Pharma Inc. (ALPMY), another stock in the Medical sector, has a year-to-date return of 0.9% and a Zacks Rank of 1 (Strong Buy), with its EPS consensus estimate increasing by 15.2% over the past three months [5][6]

Core Viewpoint - Alpha Cognition Inc. (ACOG) is showing potential for a bullish breakout as it has reached a key support level and experienced a "golden cross" in its moving averages [1]. Group 1: Technical Indicators - ACOG's 50-day simple moving average has crossed above its 200-day simple moving average, indicating a bullish signal known as a "golden cross" [1]. - The golden cross is characterized by three stages: a downtrend followed by a crossover of the shorter moving average over the longer one, and finally an upward price movement [2]. - ACOG's shares have increased by 8.1% over the past four weeks, reinforcing the bullish sentiment [3]. Group 2: Earnings Expectations - ACOG is currently rated 2 (Buy) on the Zacks Rank, suggesting strong potential for a breakout [3]. - There have been two upward revisions in earnings expectations for the current quarter, with no downward changes, indicating positive sentiment among analysts [3]. - The Zacks Consensus Estimate for ACOG has also moved higher, further supporting the bullish outlook [3]. Group 3: Investment Consideration - Given the technical indicators and positive earnings revisions, ACOG should be considered for inclusion on investors' watchlists [5].

Core Insights - Alpha Cognition is a relatively unknown pharmaceutical company that launched its first commercial product, Zunveyl (benzgalantamine), in March for the symptomatic treatment of mild-to-moderate Alzheimer's disease [1] - The company received FDA approval for Zunveyl in July 2024, marking a significant milestone in its product development [1] Company Overview - Alpha Cognition operates in the pharmaceutical industry, focusing on treatments for Alzheimer's disease [1] - The launch of Zunveyl represents the company's entry into the market with a product aimed at addressing a critical health issue [1] Product Details - Zunveyl is specifically designed for the symptomatic treatment of mild-to-moderate Alzheimer's disease, indicating a targeted approach to a prevalent condition [1] - The approval from the FDA is a crucial step for the company, as it allows for commercial sales and distribution of Zunveyl [1]

Financial Performance - Alpha Cognition Inc. reported a quarterly loss of $0.20 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.58, and an improvement from a loss of $0.75 per share a year ago, representing an earnings surprise of 65.52% [1] - The company posted revenues of $2.93 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 26.78%, compared to zero revenues a year ago [2] Stock Performance - Alpha Cognition Inc. shares have increased approximately 16.5% since the beginning of the year, outperforming the S&P 500's gain of 0.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.84 on revenues of $0.96 million, and for the current fiscal year, it is -$2.93 on revenues of $10.03 million [7] - The estimate revisions trend for Alpha Cognition Inc. is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Alpha Cognition Inc. belongs, is currently in the top 28% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Financial Data and Key Metrics Changes - For Q1 2025, the operating loss decreased to $3.7 million from $4.4 million in Q1 2024, attributed to initial net product revenues from ZUNVEL of $347,000 and recognized licensing revenue of $2.6 million from CMS [10][11] - The net loss for Q1 2025 was reported at $2 million or $0.13 per share, a decrease from a loss of $5 million or $0.87 per share in the same quarter last year, driven by increased interest income and favorable changes in derivative liabilities [11][12] - As of March 31, 2025, the company had approximately $45.5 million in unrestricted cash and cash equivalents, maintaining a debt-free balance sheet [12][13] Business Line Data and Key Metrics Changes - The commercial launch of ZUNVEL for Alzheimer's treatment has begun, with initial positive feedback and prescriptions being written shortly after launch [9][15] - Approximately 500 bottles of ZUNVEL were ordered within the first five weeks post-launch, indicating strong market demand [17] - The company has generated approximately $1 million in net sales through April 30, just four weeks into the launch [18] Market Data and Key Metrics Changes - The company is in advanced discussions for additional business development deals in new territories, expecting modest royalty revenue from the CMS deal in 2026 [5][6] - ZUNVEL became reimbursable by Medicare as of April 1, 2025, facilitating access in the long-term care segment [16] Company Strategy and Development Direction - The company aims to establish ZUNVEL as a core therapy in the long-term care market, focusing on building prescription volume and expanding its sales team gradually [9][10] - The strategy includes engaging with key plans for broader market access and monitoring prescription volume trends to support future contracting efforts [20][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early commercial traction of ZUNVEL, with qualitative feedback from healthcare professionals being overwhelmingly positive [23][24] - The company anticipates that the capital raised will be sufficient to reach a positive cash flow position by year three if execution aligns with the plan [9][13] Other Important Information - The company has received patent approval for ZUNVEL, adding to its intellectual property portfolio and providing additional protection through 2044 [7][8] - Management is actively engaging in promotional strategies, including digital programs and webinars, to enhance awareness and adoption of ZUNVEL [20][48] Q&A Session Summary Question: Can you provide details on repeat prescribers and their expected evolution? - More than half of the 100 unique accounts that placed orders have already reordered, indicating initial engagement and potential for growth [32] Question: What is the length of time patients have been on therapy? - Patients have been on therapy since April 1, with some on the drug for up to six weeks, and management expects patients to remain on the drug as long as it is effective and tolerated [30] Question: What are the current prior authorization requirements for ZUNVEL? - Prior authorization requirements have been relatively simple, with many plans requiring just a checkbox confirmation rather than extensive documentation [36] Question: What is the company's strategy for contracting in the next few months? - The company is engaged in discussions with key plans and expects to see progress in contracting as they monitor initial utilization trends [39] Question: How does the company view the market beyond Medicare? - Currently, the focus is on Medicare Part D plans, with plans to pursue commercial contracts in the future as the product gains traction [42] Question: What promotional strategies are being considered for ZUNVEL? - The current focus is on maximizing impact within the nursing home setting, with plans for sampling and broader advertising strategies as the company expands into neurology [48]